tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Ross Osborn, 120 are a BUY (91.6%), 11 are a HOLD (8.4%).
Analyst Ross Osborn, currently employed at CANTOR FITZGERALD, carries an average stock price target met ratio of 35.14% that have a potential upside of 43.99% achieved within 118 days.
Ross Osborn’s has documented 254 price targets and ratings displayed on 21 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on CVRX, CVRx at 06-Nov-2025.
Analyst best performing recommendations are on NPCE (NEUROPACE).
The best stock recommendation documented was for NPCE (NEUROPACE) at 5/14/2025. The price target of $17 was fulfilled within 1 day with a profit of $1.4 (8.97%) receiving and performance score of 89.74.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Hold
$2
$-0.32 (-13.79%)
$1.5
1 months 12 days ago
(11-Nov-2025)
11/11 (100%)
$0.14 (7.53%)
150
Buy
$2
$-0.32 (-13.79%)
$1.8
1 months 13 days ago
(10-Nov-2025)
3/4 (75%)
$0.25 (14.29%)
150
Hold
$1.5
$-0.82 (-35.34%)
$2
5 months 28 days ago
(25-Jun-2025)
6/6 (100%)
$0.28 (22.95%)
14
Buy
$3
$0.68 (29.31%)
$4
7 months 14 days ago
(09-May-2025)
1/3 (33.33%)
$1.88 (167.86%)
40
Buy
$3
$0.68 (29.31%)
$3
8 months 13 days ago
(10-Apr-2025)
5/13 (38.46%)
$1.62 (117.39%)
123
Which stock is Ross Osborn is most bullish on?
Which stock is Ross Osborn is most reserved on?
What Year was the first public recommendation made by Ross Osborn?
